Introduction
============

Premature fusion of cranial sutures with resultant cranial distortion is termed craniosynostosis. The treatments for craniosynostosis are diverse, ranging from cranial molding helmet to distraction osteogenesis [@B1], which must be performed within one year of birth to allow the affected bones to be resolved and regenerated without further defects [@B2]. Distraction osteogenesis is usually accompanied by relatively high blood loss and the subsequent need for blood transfusion in children aged \< 1 year.

Tranexamic acid (TXA) is a synthetic lysine analog that inhibits the proteolytic action of plasmin on fibrin clots and platelet receptors, thereby inhibiting fibrinolysis [@B3], [@B4]. It is efficient in reducing blood loss during surgery [@B5]-[@B8]. Currently, there are no concrete protocols for its use; however, there are reports on its population pharmacokinetics in different surgeries [@B5], [@B9], [@B10]. The hemostatic efficacy of TXA in children undergoing distraction osteogenesis has not been fully described.

Rotational thromboelastometry (ROTEM^TM^) is used in the perioperative management of hemorrhage [@B11] and transfusion [@B12], [@B13]. It is effective in reducing the need for the transfusion of any allogenic blood product. Additionally, it is substantially cost-effective [@B14].

The goals of this prospective, randomized, double-blind, placebo-controlled study were to evaluate the effects of TXA infusion based on its population pharmacokinetics by assessing blood loss and transfusion requirement in children undergoing distraction osteogenesis for craniosynostosis and to observe the impact of TXA on overall hemostasis by performing ROTEM^TM^ analysis.

Materials and Methods
=====================

Study participants
------------------

The study protocol was approved by the Institutional Review Board of the Severance Hospital of the Yonsei University Health System (Seoul, South Korea; IRB No. 4-2014-0274; June 3, 2014) and registered at <http://clinicaltrials.gov> (NCT02180321). Written informed consent was obtained from the parent or legal guardian of each patient. Fifty children who were scheduled for distraction osteogenesis for craniosynostosis were recruited in this study. Exclusion criteria were as follows: platelet count (PLT), \< 50 × 10^3^/μL; prothrombin time (PT) or activated partial thromboplastin time (aPTT) \> 1.5 times the reference value; history of convulsive seizure, epilepsy, or brain surgery; treatment with a non-steroidal anti-inflammatory agent within the previous 2 days; treatment with aspirin within 14 days prior to surgery; and known allergy to TXA. Patients were evenly assigned to two groups (TXA or control) using computer-generated randomized tables. The group allocations were noted in sequentially numbered, sealed, and opaque envelopes. A research assistant who was not a study investigator opened the envelopes and prepared the infusions according to the group allocations. Besides the designated research assistant who prepared the study drugs, all study participants and care providers were blinded to the randomization. None of the patients received any antifibrinolytic agent prior to surgery.

Management of anesthesia
------------------------

The following standardized general anesthesia protocol was used: induction with 2 mg/kg propofol and 1 μg/kg fentanyl, neuromuscular blockade with 0.6 mg/kg rocuronium bromide, maintenance with desflurane or sevoflurane in an oxygen-air mixture (fraction of inspired oxygen, 0.5), and administration of intermittent bolus doses of fentanyl and rocuronium. A central venous catheter was placed in the femoral or internal jugular vein, whereas an arterial catheter was placed in the radial artery. Urine output was monitored using a urinary catheter. Rectal temperature was measured and maintained at normothermic levels with a forced-air blanket throughout the surgery. TXA was administered as an intravenous loading dose of 10 mg/kg over 15 min, followed by continuous intravenous infusion at 5 mg/kg/h from the beginning of the surgery until skin closure [@B5]. Normal saline was similarly administered throughout the surgery to the control group.

Transfusion strategies
----------------------

The need for perioperative transfusion was determined according to the transfusion guidelines and agreement by both the surgical and anesthesia care teams [@B11], [@B15] as follows: packed red blood cells (RBC) transfusion in response to early clinical signs of circulatory shock, significant decrease in blood pressure with a hematocrit (Hct) \< 30%, acute intraoperative blood loss ≥ 15% of estimated blood volume (EBV), Hct \< 24% with signs of anemia, and clinical coagulopathy requiring hemostatic blood product transfusion (PLT \< 50 × 10^3^/μL or international normalized ratio \> 2 times the reference value) with either excessive microvascular bleeding or active bleeding [@B11], [@B16]. Blood products were filtered and irradiated prior to transfusion.

Hemoglobin/Hct, PLT, PT, and aPTT were determined before the study drugs were administered, serially at every 60 min during surgery, at the end of the surgery, and on postoperative days 1 and 2. The levels of fibrinogen and D-dimer were measured before the study drugs were administered and at the end of the surgery.

Distraction osteogenesis
------------------------

All the patients underwent distraction osteogenesis to correct cranial deformities. Osteotomy was performed according to the relevant design for the specific diagnosis of craniosynostosis. After successful osteotomy and bone flap elevation, distraction devices (Jeil Medical Corp., Seoul, Republic of Korea) were fixed. The number of distraction devices required was determined based on the type of osteotomy [@B1], [@B17]. Patients were monitored in the neurosurgical intensive care unit for 1-2 days after surgery.

Outcome measures
----------------

Due to the inaccuracy in estimating blood loss during surgery, blood loss was calculated by the anesthesiologist using a previously adopted formula for this patient population [@B6], [@B18], [@B19]:
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where ERCV is EBV × Hct/100.

EBV is 80 mL/kg for infants younger than 12 months and 75 mL/kg for children older than 12 months. ERCV~transfused~ was calculated as follows:
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Routine fluid management during surgery consisted of continuous administration of balanced crystalloid with additional SD 1:4 solution (0.2% NaCl with dextrose). The amount of fluid administered was determined based on preoperative fasting time, intraoperative deficits, and basal fluid maintenance. Colloid \[hydroxyethyl starch (6%, 130/0.4) in a balanced electrolyte solution, Volulyte; Fresenius Kabi, Schelle, Belgium\] up to 20 mL/kg/day was administered in case of acute and massive perioperative blood loss prior to the initiation of blood product preparation and transfusion. Controlled hypotension was not performed during surgery. The scalp was infiltrated with local anesthetics containing epinephrine during the surgical procedure.

ROTEM^TM^ analyses were performed three times during the study period: prior to administration of the study drugs (T0), immediately after surgery (T1), and 24 h after surgery (T2). Blood samples for ROTEM^TM^ analyses were drawn from an indwelling arterial catheter. Clot formation, propagation, and strength were evaluated extrinsically (EXTEM, extrinsically activated test with tissue factor) and intrinsically (INTEM, intrinsically activated test using ellagic acid). In addition, an extrinsically activated test was performed using the platelet-blocking substance cytochalasin D (FIBTEM, fibrin-based extrinsically activated test with tissue factor and the platelet inhibitor cytochalasin D) for the separate evaluation of functional fibrin polymerization without platelet activity. All ROTEM^TM^ analyses were performed according to standard protocols with a minimum running time of 60 min by a designated experienced anesthesiologist (JWL).

During regular postoperative follow-ups, the patients were examined for any clinical evidence of TXA-related adverse events, such as clinically evident thromboembolic or neurologic events, until 3 months after the surgery.

Statistical analysis
--------------------

The primary objective of this study was to compare blood loss and transfusion requirement between the TXA and control groups. The secondary objective was to evaluate the hemostatic effect of TXA by performing ROTEM^TM^ analyses. For a statistical power of 0.80, a group size of at least 23 was obtained from calculations to detect a large effect size of 0.85 by using a two-tailed test (α = 0.05) [@B6]. Considering potential dropout rates, investigators decided to enroll 25 patients per group. Data are presented as mean ± standard deviation or median (interquartile range) for continuous variables based on the Kolmogorov-Smirnov normality test or number of patients (percentage) for categorical variables. Student\'s *t*-test or Mann-Whitney *U*-test was used depending on the underlying distribution to detect differences in results between the TXA and control groups. Repeatedly measured variables, such as hemoglobin/Hct, PLT, PT, and aPTT were analyzed using linear mixed models with Bonferroni correction. Statistical analyses were performed using SPSS for Windows (version 23.0; SPSS Inc., Chicago, IL, USA). *P* \< 0.05 was considered statistically significant.

Results
=======

Fifty patients, aged 4 months to 5 years, were enrolled in the study from July 2014 to March 2016. Two patients in the TXA group were excluded from the analysis because of an error in the ROTEM^TM^ analysis. Patient demographics and surgery-related data were comparable between the two groups (Table [1](#T1){ref-type="table"}).

Intraoperative blood loss was significantly lower in the TXA group than it was in the control group (81 vs. 116 mL/kg; *P* = 0.003). Although the same transfusion guidelines were followed for both groups, the amount of blood products administered intraoperatively was significantly lower in the TXA group than it was in the control group \[packed RBC, 49 vs. 65 mL/kg, *P* = 0.010; fresh frozen plasma (FFP), 19 vs. 28 mL/kg, *P* = 0.038\]. Moreover, no patient in the TXA group was administered a blood product postoperatively, except for two patients who were administered FFP on postoperative day 1 (Table [2](#T2){ref-type="table"}). The amount of crystalloid administered during surgery was comparable between the two groups; however, a significantly smaller volume of colloids was administered intraoperatively in the TXA group than in the control group (17 vs. 20 mL/kg, *P* = 0.026). Although the number of patients treated with diuretics and the amount of diuretics administered perioperatively were comparable between the two groups (data not shown), urine output was lower in the TXA group than it was the control group on postoperative day 1 (59.4 vs. 80.0 mL/kg, *P* = 0.010; Table [2](#T2){ref-type="table"}).

Preoperative baseline Hct, PLT, fibrinogen level, PT, aPTT, and D-dimer level did not differ significantly between the two groups. However, Hct was significantly higher in the TXA group than it was in the control group at the end of surgery and on postoperative day 2 \[32 vs. 29% (*P* = 0.048) and 35 vs. 30% (*P* = 0.034), respectively\]. Similarly, PLT was significantly higher in the TXA group on postoperative day 2 (267 vs. 194 × 10^3^/μL, *P* = 0.010; Fig. [1](#F1){ref-type="fig"}A and [1](#F1){ref-type="fig"}B, respectively). Postoperative aPTT at the end of surgery was significantly longer in the control group than it was in the TXA group (36 vs. 41 s, *P* = 0.028; Fig. [1](#F1){ref-type="fig"}D). Furthermore, D-dimer level dramatically increased after surgery in the control group; however, the increase in D-dimer level was suppressed in the TXA group (Fig. [1](#F1){ref-type="fig"}F). Compared with preoperative baseline values, PT was significantly prolonged and fibrinogen level was significantly reduced after surgery in both groups (Fig. [1](#F1){ref-type="fig"}C and [1](#F1){ref-type="fig"}E); however, these parameters were comparable between the two groups.

ROTEM^TM^ analyses showed no significant differences in EXTEM, INTEM, or FIBTEM between the two groups (Fig. [2](#F2){ref-type="fig"}); however, differences in some ROTEM^TM^ data were significant when preoperative baseline values were compared with the respective values at the end of surgery. For EXTEM, initiation and propagation of clot formation were delayed at the end of surgery in the control group. In addition, clot strength, which is based on clot amplitude at 10 min after clotting time (A10) and maximum clot firmness (MCF), reduced in both groups (Fig. [2](#F2){ref-type="fig"}A-D). For INTEM, prolonged clot propagation, decreased clot strength, increased clot formation time (CFT), and decreased A10 and MCF were observed at the end of surgery in both groups (Fig. [2](#F2){ref-type="fig"}E-H). Furthermore, lysis index at 30 min (percentage of clot firmness remaining after 30 min in relation to MCF), lysis onset time (defined as the time needed for clot firmness to decrease by 15% of MCF), and maximum clot lysis were determined to assess the degree of fibrinolysis. No intergroup differences were noted in the lysis parameters. Changes in INTEM and EXTEM parameters from the preoperative baseline values were not observed on postoperative day 1. Although fibrinogen levels significantly reduced in both groups, clot strength, based on the results of the FIBTEM analysis, significantly reduced only in the control group after surgery (Fig. [2](#F2){ref-type="fig"}I and 2J).

Mechanical ventilation time, which indicates the total duration of mechanical ventilation applied during the intraoperative and postoperative periods, was significantly shorter in the TXA group than it was in the control group (327 vs. 378 min, *P* = 0.024; Table [3](#T3){ref-type="table"}). The number of patients with postoperative complications, such as pulmonary edema, pneumonia, and transfusion-related acute lung injury, was significantly higher in the control group than it was in the TXA group (0 vs. 4 \[16%\], *P* = 0.047). The total lengths of postoperative stay in the neurovascular care unit and the hospital were comparable between the two groups (Table [3](#T3){ref-type="table"}). There was no incidence of convulsive seizure or a thromboembolic event in any patient during the study.

Discussion
==========

TXA administration based on dosing schemes derived from population pharmacokinetic analyses was shown to reduce blood loss and transfusion requirement. Although ROTEM^TM^ analysis failed to show TXA-induced changes in systemic hemostasis, it indicated significant changes in D-dimer levels. Furthermore, changes in FIBTEM indicated the preserved quality of fibrin-based clot at the end of surgery with subsequent hemostatic functional benefit following TXA administration [@B20]-[@B23].

The efficacy of TXA in reducing blood loss may differ depending on its plasma level [@B24], [@B25]. A previous pharmacokinetic study showed that systemic clearance of TXA was significantly reduced in patients weighing ≤ 10 kg or aged ≤ 12 months. This suggests that caution should be taken when administering TXA to such patients, especially those scheduled for surgeries that result in massive bleeding and/or high transfusion requirement [@B5]. The results of recent investigations on the population pharmacokinetics of TXA have aided the development of a more precise protocol for TXA administration to pediatric patients [@B5], [@B9], [@B10].

TXA-induced hemostasis involves inhibition of plasminogen-plasmin interactions on the surface of fibrin, thereby preventing fibrin degradation [@B3]. D-dimer is a protein product of cross-linked fibrin degradation, whose level in the blood elevates during hyperfibrinolysis and massive hemorrhage caused by fibrinolysis [@B26], [@B27]. D-dimer level had also shown clinical significance as a predictor of patient morbidity and transfusion requirement [@B29]. Although D-dimer could not be considered the gold standard measure of fibrinolysis, several studies had reported the antifibrinolytic effect of TXA related to blood loss and the changes in the levels of fibrinolysis markers, such as D-dimer, in various types of surgeries [@B28], [@B30]. The suppressed increase in D-dimer level in the TXA group during the postoperative period observed in this study could be due to the antifibrinolytic action of TXA (Fig. [1](#F1){ref-type="fig"}F).

The antifibrinolytic activity of TXA resulted in reduced transfusion requirement until postoperative day 2 in this study. Although the mean half-life of TXA is 120 min [@B31], its hemostatic effect in patients, including children undergoing surgery for craniosynostosis treatment, can extend up to 24 h after it is discontinued [@B3], [@B6], [@B32]. This is considered as a residual effect at the surgical site, rather than a systemic effect [@B6], [@B33], [@B34]. However, despite the long-term effect of TXA in reducing the amount of transfusion required, no statistically significant difference was found between the two groups regarding the amount of blood lost during the postoperative period. Such lack of statistical significance may be attributed to the excessive hemorrhage in both groups, regardless of TXA administration. Although TXA effectively reduced intraoperative hemorrhage, the extent of blood loss (average, \> 80 mL/kg) was equivalent to the total blood volume of an average 1-year-old child weighing approximately 10 kg. The observed dramatic drop in PLT and fibrinogen level after surgery could have been caused by the massive hemorrhage.

ROTEM^TM^ analysis was performed before and after surgery to evaluate the changes in overall coagulation status. Prolonged CFT and a substantial drop in A10 and MCF in the EXTEM test at the end of surgery were attributed, in part, to decreased PLT and fibrinogen level from their respective baseline values in both groups. Significant blood loss was treated with packed RBC and FFP transfusions in the control group, which could have contributed to the reduced PLT and fibrinogen level. Consequently, no significant differences in the results of the ROTEM^TM^ analysis were found between the two groups. In the control group, FIBTEM A10 and MCF, which are indicative of clot strength and fibrinogen activity, significantly reduced compared to their respective baseline values (Fig. [2](#F2){ref-type="fig"}I and 2J). This might have been due to a dilution effect caused by the significantly large amount of FFP transfused during surgery. Therefore, transfusing more concentrated fibrinogen supplements, such as cryoprecipitates, may be a better option when treating children with a smaller circulation volume. Moreover, although it had been restricted to 20 mL/kg/day, the significantly large amount of colloid as a volume expander prior to transfusion in the case of acute and massive perioperative bleeding, may have affected the coagulation status and interfered with the ROTEM^TM^ analysis. Colloids enhance fibrinolysis by diminishing α~2~-antiplasmin-plasmin interactions [@B35], thereby impeding fibrin formation and reducing fibrinogen-dependent clot strength [@B36], [@B37]. Although clinical data on the safe use of colloids in children are insufficient, some studies have shown that colloid infusions do not affect renal and coagulation systems in children [@B38], [@B39]. One noticeable benefit of TXA during surgery is the decreased incidence of postoperative respiratory-related complications. Transfusion of packed RBC (\> 60 mL/kg) and/or hemostatic products, such as FFP, platelet concentrates, and cryoprecipitates, was found to be an independent predictor of the occurrence of postoperative cardiorespiratory and hematological events [@B40]. The substantial number of transfusions received by patients in the control group may have prolonged mechanical ventilation time and resulted in a higher probability of respiratory-related complications (Table [3](#T3){ref-type="table"}).

This study has several limitations. First, only packed RBC, FFP, and platelet concentrates were transfused due to the limited clinical availability of fibrinogen and cryoprecipitates. Second, the study design had limited the use of ROTEM^TM^ analyses as the reference values for data interpretation, rather than the transfusion guidelines. Thirdly, in addition to EXTEM, INTEM, and FIBTEM, APTEM (extrinsically activated test containing aprotinin) could have been performed to enrich hemolytic profiles. This is because APTEM is useful when predicting the effects of antifibrinolytic agents on hyperfibrinolysis [@B41]. Moreover, randomized studies with a greater number of patients will be required to further investigate the discrepancy between the changes in the amount of blood loss and transfusion requirement and ROTEM^TM^ analysis, especially with lysis parameters.

In conclusion, results of this study show that TXA administration based on the dosage regimen predicted from population pharmacokinetic analysis can be effective in reducing blood loss and transfusion requirement in pediatric patients undergoing distraction osteogenesis for craniosynostosis. Furthermore, the effects of antifibrinolytic agents on systemic hemostasis must be investigated in viscoelastic studies.
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###### 

Patient Characteristics and Surgery-related Data.

                                            TXA (n=23)     Control (n=25)   *P*-value
  ----------------------------------------- -------------- ---------------- -----------
  Age (months)                              12 (7-22)      14 (8-30)        0.380
  Male, n (%)                               14 (61)        10 (40)          0.153
  Height (cm)                               76.7 ± 8.1     80.0 ± 11.4      0.256
  Weight (kg)                               10.1 ± 2.3     10.7 ± 2.6       0.430
  Preoperative Medical Problem, n (%)^\*^   11 (48)        13 (52)          0.775
  Concomitant Features, n (%)^\*\*^         6 (26)         8 (32)           0.656
  Diagnosis, n (%)                                                          
  Sagittal                                  8 (35)         7 (28)           0.616
  Metopic                                   2 (9)          0 (0)            0.136
  Unilateral coronal                        5 (22)         2 (8)            0.182
  Bilateral coronal                         2 (9)          3 (12)           0.711
  Lambdoid                                  2 (9)          3 (12)           0.711
  Multiple                                  4 (17)         10 (40)          0.088
  Duration of Surgery (min)                 264.0 ± 75.1   262.6 ± 48.4     0.939
  Duration of Anesthesia (min)              326.1 ± 58.4   352.4 ± 45.3     0.086

Values are mean ± standard deviation, median (interquartile range), or number of patients (percentage).

TXA: tranexamic acid; ASA: American Society of Anesthesiology physical status classification.

\* Preoperative medical problems: Abnormal electrocardiogram, abnormal chest x-ray, mildly increased serum liver enzyme levels (aspartate aminotransferase and alanine aminotransferase)

\*\*Concomitant features: Structural heart disease, hypothyroidism, hydrocephalus, diagnosed with Crouzon, Apert syndrome, Chiari malformation.

###### 

Perioperative Fluid Management Between Groups.

  -----------------------------------------------------------------------------------------------------------
                                                                    TXA\               Control\   *P*-value
                                                                    (n=23)             (n=25)     
  ---------------------------------------------- ------------------ ------------------ ---------- -----------
  **Intraoperative period**                      **Input**                                        

  Crystalloid (mL/kg)                            35.5 (26.1-41.2)   29.1 (21.7-38.2)   0.151      

  Colloid (mL/kg)                                16.7 (14.1-20.0)   20.0 (16.7-20.0)   0.038      

  Packed RBC (mL/kg)                             48.8 ± 16.8        65.2 ± 24.2        0.010      

  FFP (mL/kg)                                    19.4 ± 13.0        28.1 ± 15.1        0.038      

  platelet concentrate (mL/kg)                   5.9 (0-12.9)       10 (2.1-16.9)      0.217      

  **Number of patients receiving transfusion**                                                    

  Packed RBC                                     23 (100)           25 (100)           \> 0.999   

  FFP                                            23 (100)           25 (100)           \> 0.999   

  platelet concentrate                           14 (61)            20 (80)            0.149      

  **Output**                                                                                      

  Blood loss (mL/kg)                             80.6 ± 33.3        115.6 ± 43.6       0.003      

  Urine Output (mL/kg)                           29.8 (18.2-33.8)   29.8 (18.7-43.3)   0.828      

  **Postoperative day 1**                        **Input**                                        

  Crystalloid (mL/kg)                            78.5 ± 23.1        83.1 ± 29.8        0.557      

  Colloid (mL/kg)                                \-                 \-                            

  Packed RBC (mL/kg)                             \-                 0 (0-7.4)          0.003      

  FFP (mL/kg)                                    0 (0-0)            0 (0-0)            \> 0.999   

  platelet concentrate (mL/kg)                   \-                 0 (0-0)            0.090      

  **Number of patients receiving transfusion**                                                    

  Packed RBC                                     0                  8 (32)             0.003      

  FFP                                            2 (9)              2 (8)              \>.999     

  PLT                                            0                  3 (12)             0.090      

  **Output**                                                                                      

  Blood loss (mL/kg)                             5.3 (3.4-8.0)      4.1 (2.3-7.2)      0.252      

  Urine Output (mL/kg)                           59.4 (48.4-67.0)   80.0 (54.0-95.6)   0.010      

  **Postoperative day 2**                        **Input**                                        

  Crystalloid (mL/kg)                            57.4 (44.4-64.5)   54.1 (48.0-74.3)   0.570      

  Colloid (mL/kg)                                \-                 \-                            

  Packed RBC (mL/kg)                             \-                 0 (0-0)            0.025      

  FFP (mL/kg)                                    \-                 0 (0-0)            0.337      

  platelet concentrate (mL/kg)                   \-                 \-                 \> 0.999   

  **Number of patients receiving transfusion**                                                    

  Packed RBC                                     0                  5 (20)             0.025      

  FFP                                            0                  1 (4)              0.337      

  platelet concentrate                           0                  0                  \> 0.999   

  **Output**                                                                                      

  Blood loss (mL/kg)                             1.3 (0.8-2.1)      1.3 (0.9-2.1)      0.926      

  Urine Output (mL/kg)                           64.6 (56.5-83.0)   66.9 (46.3-94.6)   0.703      
  -----------------------------------------------------------------------------------------------------------

Values are mean ± standard deviation, median (interquartile range), or number of patients (percentage). TXA: tranexamic acid; OR: odds ratio; packed RBC: packed red blood cells; FFP: fresh frozen plasma.

###### 

Postoperative Outcomes.

  ---------------------------------------------------------------------------------------------------------------
                                          TXA\           Control\       Estimated Treatment Effect   *P*- value
                                          (n=23)         (n=25)                                      
  --------------------------------------- -------------- -------------- ---------------------------- ------------
  NCU stay (h)                            20 (19-21.5)   22 (19-24.5)   -1.0 \[-3.0 to 0.5\]         0.141

  Mechanical ventilation time (min)^\*^   326.5 ± 65.8   377.7 ± 84.5   51.2 \[-95.4 to -6.9\]       0.024

  Complications, n(%)^\*\*^               0 (0)          4 (16)         0.48 \[0.35 to 0.65\]        0.047

  Hospital stay (days)                    10.1 ± 3.6     10.9 ± 5.1     0.8 \[-3.4 to 1.8\]          0.542
  ---------------------------------------------------------------------------------------------------------------

Values are mean ± standard deviation, median (interquartile range), or number of patients (percentage). Estimated treatment effect is presented as mean difference \[95% confidence interval\] or relative risk \[95% confidence interval\].

TXA: tranexamic acid; NCU: neurovascular care unit.

\* Total duration of mechanical ventilation applied during intraoperative and postoperative periods.

\*\* Any event of pulmonary edema, pneumonia, or transfusion-related acute lung injury.
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